Q32 Bio Inc. (QTTB) Income Statement
QTTB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsQTTB revenue and net income
Where QTTB's revenue goes
2025Each bar shows an amount and its share of revenue. QTTB kept 55.5% of revenue as net income.
QTTB profit margins
QTTB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | +100.7% | +81.9% | — |
| Gross profit | — | +100.7% | +81.9% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
QTTB quarterly EPS vs estimates
Q32 Bio beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.36).
QTTB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53.7M | $0 | $0 | $6.7M | $34.0M | $2.7M | $1.7M | $5.3M | $0 | $0 |
| Cost of revenue | $391,000 | $487,000 | $499,000 | $2.6M | $9.5M | $0 | $0 | $0 | $684,214 | $239,797 |
| Gross profit | $53.7M | −$487,000 | −$6.7M | $6.7M | $24.4M | $2.7M | $1.7M | $5.3M | −$684,214 | −$239,797 |
| Research & development | $19.2M | $48.1M | $31.7M | $35.8M | $29.9M | $100.4M | $89.4M | $47.9M | $21.4M | $5.7M |
| Sales, general & admin | $17.7M | $18.0M | $9.9M | $10.1M | $6.8M | — | — | — | — | — |
| Total operating expenses | $36.8M | $66.1M | $41.6M | $45.9M | $36.7M | $124.1M | $105.3M | $64.0M | $29.0M | $9.8M |
| Operating income | $16.9M | −$66.1M | −$48.3M | −$39.2M | −$36.7M | −$130.3M | −$109.9M | −$59.9M | −$29.7M | −$10.0M |
| Interest income | $2.2M | $3.9M | — | — | — | — | — | — | — | — |
| Interest expense | $1.1M | $1.1M | $1.5M | — | — | — | — | — | — | — |
| Income before taxes | $29.8M | −$47.7M | −$53.4M | −$42.7M | −$37.0M | −$128.7M | −$103.9M | −$55.6M | −$30.0M | −$8.0M |
| Income taxes | — | $21,000 | $318,000 | $62,000 | $547,000 | −$1 | — | — | −$4 | $2 |
| Net income | $29.8M | −$47.7M | −$53.7M | −$42.8M | −$37.6M | −$128.7M | −$103.9M | −$55.6M | −$30.0M | −$8.0M |
| EBITDA | $31.3M | −$44.5M | −$47.8M | −$38.9M | −$36.6M | −$121.4M | −$97.6M | −$58.6M | −$29.3M | −$7.8M |
| EPS (diluted) | $2.30 | −$3.01 | −$1.96 | −$1.98 | −$30.42 | −$50.40 | −$44.46 | −$16.69 | −$0.32 | — |
| Gross margin | 100.0% | — | — | 100.0% | 71.9% | 100.0% | 100.0% | 100.0% | — | — |
| Operating margin | 31.5% | — | — | −589.8% | −108.0% | −4,821.0% | −6,599.2% | −1,126.0% | — | — |
| Net margin | 55.5% | — | — | −643.6% | −110.6% | −4,762.9% | −6,237.5% | −1,044.3% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $53.7M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.9M |
| Cost of revenue | $85,000 | $90,000 | $90,000 | $91,000 | $91,000 | $119,000 | $120,000 | — | $121,000 | $123,000 | $124,000 | $124,000 |
| Gross profit | −$85,000 | −$90,000 | $53.7M | −$91,000 | −$91,000 | −$119,000 | −$120,000 | — | −$121,000 | −$123,000 | −$14.7M | $1.9M |
| Research & development | $4.3M | $3.2M | $3.3M | $3.6M | $5.2M | $7.1M | $10.5M | $14.3M | $13.4M | $9.8M | $8.3M | $7.5M |
| Sales, general & admin | $4.9M | $4.5M | $4.5M | $4.0M | $4.0M | $5.1M | $4.0M | $4.5M | $4.6M | $5.0M | $2.8M | $2.2M |
| Total operating expenses | $9.0M | $7.7M | $7.9M | $7.6M | $9.2M | $12.2M | $14.5M | $18.8M | $17.9M | $14.8M | $11.1M | $9.7M |
| Operating income | −$9.1M | −$7.7M | $45.9M | −$7.6M | −$9.2M | −$12.2M | −$14.5M | −$18.8M | −$17.9M | −$14.8M | −$25.8M | −$7.8M |
| Interest income | — | — | $400,000 | $500,000 | $600,000 | $700,000 | — | $1.2M | — | — | — | — |
| Interest expense | $800,000 | $200,000 | $200,000 | $300,000 | $300,000 | $300,000 | — | $300,000 | $1.7M | $500,000 | — | — |
| Income before taxes | −$8.9M | −$7.6M | $57.7M | −$7.4M | −$9.5M | −$11.0M | −$14.2M | −$17.6M | −$17.0M | $1.2M | −$26.8M | −$14.0M |
| Income taxes | — | — | — | — | — | — | $21,000 | $14.3M | $1.4M | $176,000 | $253,000 | $65,000 |
| Net income | −$8.9M | −$7.6M | $57.7M | −$7.4M | −$9.5M | −$11.0M | −$14.2M | −$17.6M | −$17.0M | $1.0M | −$27.1M | −$14.0M |
| EBITDA | −$8.9M | −$7.6M | $58.0M | −$7.0M | −$9.1M | −$12.1M | $6.7M | −$17.2M | −$17.8M | −$14.7M | −$25.7M | −$7.7M |
| EPS (diluted) | −$0.44 | −$0.54 | $4.58 | −$0.60 | −$0.78 | −$0.90 | −$1.16 | −$1.46 | −$1.42 | $1.03 | −$0.28 | −$0.57 |
| Gross margin | — | — | 100.0% | — | — | — | — | — | — | — | — | 100.0% |
| Operating margin | — | — | 85.4% | — | — | — | — | — | — | — | — | −419.5% |
| Net margin | — | — | 107.4% | — | — | — | — | — | — | — | — | −754.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in QTTB's financial statements (latest annual report filed March 10, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
QTTB financial results
In fiscal year 2025 (ended December 31, 2025), Q32 Bio reported revenue of $53.7 million. It had net income of $29.8 million, a net profit margin of 55.5%. Diluted earnings per share came to $2.30. Over five years revenue grew at an average rate of 81.9% a year.
See the QTTB stock overview for the latest quote and news, or the QTTB chart for price history and technical indicators.
QTTB income statement FAQ
What is Q32 Bio's annual revenue?
Q32 Bio reported total revenue of $53.7 million for fiscal year 2025, which ended on December 31, 2025.
Is Q32 Bio profitable?
Yes. Q32 Bio reported net income of $29.8 million in fiscal 2025, a net profit margin of 55.5%; its operating margin was 31.5%.
What is Q32 Bio's gross margin?
Q32 Bio's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Q32 Bio kept $100 after the direct cost of its products and services.
How much does Q32 Bio spend on research and development?
Q32 Bio spent $19.2 million on research and development in fiscal 2025, 35.6% of revenue.
How fast is Q32 Bio growing?
Revenue grew 81.9% a year on average over the last five fiscal years, from $2.7 million to $53.7 million.
What are Q32 Bio's earnings per share?
Q32 Bio earned $2.30 per diluted share in fiscal 2025, compared with $-3.01 a year earlier.
When will Q32 Bio report its next earnings?
Q32 Bio is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Q32 Bio's fiscal year end?
Q32 Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 10, 2026.